1 – 10 of 28
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial
2024) In European Urology(
- Contribution to journal › Article
- 2023
-
Mark
Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium
2023) In European Urology(
- Contribution to journal › Article
-
Mark
Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial
(
- Contribution to journal › Article
-
Mark
Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality : 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial
(
- Contribution to journal › Article
-
Mark
Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer
(
- Contribution to journal › Letter
- 2022
-
Mark
PSA : role in screening and monitoring patients with prostate cancer
2022) p.131-172(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2020
-
Mark
Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years : A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
(
- Contribution to journal › Article
-
Mark
A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy
(
- Contribution to journal › Article
- 2019
-
Mark
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men
(
- Contribution to journal › Article
-
Mark
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy
(
- Contribution to journal › Article